Explore more publications!
Wellness Focus Cayman Islands
Got News to Share?

Wellness Focus Cayman Islands: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Wellness Focus Cayman Islands.

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

January 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

Press releases published on January 27, 2026

Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
6 hours ago

Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data

Indeterminate GlobeNewswire
Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations
6 hours ago

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations

Indeterminate GlobeNewswire
Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program
6 hours ago

Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program

Indeterminate GlobeNewswire
TRIMEDX named recipient of Modern Healthcare’s Best in Business Award in Cybersecurity category
6 hours ago

TRIMEDX named recipient of Modern Healthcare’s Best in Business Award in Cybersecurity category

Indeterminate GlobeNewswire
Imviva Biotech Receives FDA Orphan Drug Designation for CTD402 for the Treatment of T-Cell Leukemia and Lymphoma
6 hours ago

Imviva Biotech Receives FDA Orphan Drug Designation for CTD402 for the Treatment of T-Cell Leukemia and Lymphoma

Indeterminate GlobeNewswire
SRx Health Solutions Allocates Further Capital to its Digital Asset Treasury Hedging Strategy, Bringing Total Allocation to $18 Million
6 hours ago

SRx Health Solutions Allocates Further Capital to its Digital Asset Treasury Hedging Strategy, Bringing Total Allocation to $18 Million

Indeterminate GlobeNewswire
Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome
6 hours ago

Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome

Indeterminate GlobeNewswire
CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer
6 hours ago

CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer

Indeterminate GlobeNewswire
NewGen to Execute Up to US$2 Million Share Repurchase Program Through Benchmark
6 hours ago

NewGen to Execute Up to US$2 Million Share Repurchase Program Through Benchmark

Indeterminate GlobeNewswire
Hydreight Technologies Inc. Announces Closing of Oversubscribed $15 Million Bought Deal LIFE Offering
6 hours ago

Hydreight Technologies Inc. Announces Closing of Oversubscribed $15 Million Bought Deal LIFE Offering

Indeterminate GlobeNewswire
ABLi Therapeutics Completes Collaboration Agreement with The Michael J. Fox Foundation to include Risvodetinib in Path to Prevention Platform Trial
7 hours ago

ABLi Therapeutics Completes Collaboration Agreement with The Michael J. Fox Foundation to include Risvodetinib in Path to Prevention Platform Trial

Indeterminate GlobeNewswire
Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’
7 hours ago

Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’

Indeterminate GlobeNewswire
Science 37 Appoints Kelly Johnston McKee as VP of Strategy & Transformation
7 hours ago

Science 37 Appoints Kelly Johnston McKee as VP of Strategy & Transformation

Indeterminate GlobeNewswire
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
7 hours ago

Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026

Indeterminate GlobeNewswire
Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
7 hours ago

Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split

Indeterminate GlobeNewswire
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN
7 hours ago

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN

Indeterminate GlobeNewswire
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
7 hours ago

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

Indeterminate GlobeNewswire
Synergy CHC Corp. (NASDAQ: SNYR) Expands FOCUSfactor® Functional Beverage Distribution Across Canada Through Walmart Canada and McKesson Canada
7 hours ago

Synergy CHC Corp. (NASDAQ: SNYR) Expands FOCUSfactor® Functional Beverage Distribution Across Canada Through Walmart Canada and McKesson Canada

Indeterminate GlobeNewswire
Cloudbreak Pharma Announces Successful End-of-Phase-2 Meeting and Alignment with FDA on Phase 3 Path Forward for CBT-004
7 hours ago

Cloudbreak Pharma Announces Successful End-of-Phase-2 Meeting and Alignment with FDA on Phase 3 Path Forward for CBT-004

Indeterminate GlobeNewswire
Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)
7 hours ago

Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions